GlassScriptPhysician profile
Thomas W Pollard
NPI 1710069885
$88,074.46
in general payments reported to CMS, 2019-2025
51 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $13K · 2021: $14K · 2022: $5,163 · 2023: $4,118 · 2024: $2,429 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $8,674 · Consulting Fee: $1,229 · Travel and Lodging: $287 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,487.13 |
| Food and Beverage | $8,673.90 |
| Consulting Fee | $1,229.00 |
| Travel and Lodging | $287.20 |
| Education | $110.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26,455.44 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Glaxosmithkline, LLC. | $19,756.30 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| United Therapeutics Corporation | $13,191.70 | 2019-2025 | Tyvaso, Tyvaso |
| Viatris Specialty LLC | $11,645.78 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $4,026.29 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Genzyme Corporation | $2,987.87 | 2021-2025 | |
| Insmed, INC. | $1,791.92 | 2019-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $1,199.64 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $919.14 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $533.54 | 2019-2023 | Opsumit, Uptravi |
| Electromed, INC. | $530.81 | 2021-2025 | Smartvest |
| Genentech USA, INC. | $508.68 | 2019-2025 | Xolair |
| Allergan, INC. | $409.86 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $372.38 | 2023-2025 | Zerbaxa, Winrevair, Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $362.34 | 2021-2025 | Glassia |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $348.78 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Advanced Respiratory, INC | $294.63 | 2020-2021 | |
| Verona Pharma, INC. | $284.04 | 2025 | Ohtuvayre |
| Pfizer INC. | $271.02 | 2019-2024 | |
| Philips North America LLC | $168.94 | 2022-2025 | (Di7) Home Pi Undivided, Vest Therapy Und |
| Mallinckrodt Hospital Products INC. | $155.84 | 2021-2023 | Acthar |
| Jazz Pharmaceuticals INC. | $141.71 | 2019-2021 | |
| Inogen, INC. | $135.32 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Abiomed | $124.03 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.16 | 2019-2023 | |
| Abbvie INC. | $108.67 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $102.63 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Novo Nordisk INC | $93.44 | 2019-2020 | |
| Inspire Medical Systems, INC. | $92.98 | 2023-2025 | Inspire |
| Harmony Biosciences LLC | $84.44 | 2022-2024 | Wakix |
| Pulmonx Corporation | $80.94 | 2023-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Amgen INC. | $69.37 | 2022-2024 | Tezspire, Prolia, Evenity |
| Lilly USA, LLC | $66.94 | 2025 | Zepbound |
| Novartis Pharmaceuticals Corporation | $65.73 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $56.91 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $43.24 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $39.19 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $38.89 | 2020-2021 | |
| Grifols USA, LLC | $38.73 | 2021 | |
| Amarin Pharma, INC. | $35.76 | 2019-2021 | |
| Eisai INC. | $35.58 | 2021 | |
| Gilead Sciences, INC. | $32.75 | 2024 | Epclusa |
| Covis Pharma Gmbh | $30.65 | 2022 | |
| Octapharma USA, INC. | $30.20 | 2024 | Panzyga |
| Edwards Lifesciences Corporation | $23.12 | 2022 | |
| Shionogi INC | $20.53 | 2022 | |
| Boston Scientific Corporation | $18.45 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.83 | 2023 | Seglentis |
| Lucid Diagnostics INC. | $13.90 | 2022 | |
| Breas Medical, INC. | $11.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pollard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.